Assessment of the Efficacy of a Sensorimotor Approach After Maximum Three Sessions in Subjects With Symptomatic Temporomandibular Dysfunction (TMD) With Hypertonia: A Prospective, Multicenter Case Study.

Osteovox6 sites in 3 countries110 target enrollmentJanuary 2016

ConditionsTemporomandibular Disorder

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Temporomandibular Disorder
Sponsor: Osteovox
Enrollment: 110
Locations: 6
Primary Endpoint: Overall relief (from 0% to 100%) based on the ratio of "complaint after treatment" to "complaint before treatment". Multiple measurements related to both pain and functional incapacity are aggregated to arrive at one reported value: complaint
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The study aims to demonstrate the efficacy of the sensorimotor approach developed by A. Piron (taught to the patient in three sessions) regarding three parameters related to TMD: facial pain, functional incapacities and hypertonia.

The subjects in the study are 18 to 77 years old and present the following conditions: a TMD disorder caused or aggravated by hypertonia and responsible for cervico-maxillo-facial pain and/or a functional incapacity in the last 30 days.

Registry

clinicaltrials.gov

Start Date

January 2016

End Date

December 31, 2017

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Osteovox

Responsible Party

Principal Investigator

L'HOMME Sébastien

Dentist

Osteovox

Eligibility Criteria

Inclusion Criteria

•Male or female subjects aged 18 to 77 years old.
•Subjects presenting the following 3 characteristics:
•A TMD disorder (objectivized by the DC/TMD 2014);
•Facial pain in the last 30 days (objectivized by the Graded Chronic Pain Scale version 2.0 (GCPS v2.0)) and/or functional incapacity (chewing, mobility, verbal and emotional communication) in the last 30 days (objectivized by the Jaw Functional Limitation Scale 20 (JFLS-20));
•Hypertonia (objectivized by the Oral Behaviors Checklist (OBC) short version and the Explanatory Model Scale).
•Subjects who agree to comply with the requirements of the study. Subjects who are of age (and know how to read and write) who have given their informed, explicit consent in advance to any procedure related to the trial, the study or the investigation conducted on human beings, with the objective of developing knowledge specific to the exercise of health care professions, as set out in Royal Decree No. 78 of 10 November 1967 on the practice of the health care professions (Act of 27 December 2005).
•Subjects insured under social security.

Exclusion Criteria

•Any subject presenting at least one of the following criteria may not be included:
•Significant medical problems involving the following conditions:
•Severe or progressive pathology (psychiatric, neurological, cardiopulmonary, renal, hepatic, endocrinological, hematological, neoplastic, infectious, metabolic or allergic).
•Any acute trauma of the temporomandibular joint (trauma within the last 72 hours).
•Severe anxiety or severe depression, as defined by a score greater than or equal to 15 on the HAD.
•Pregnant women
•Criteria related to prior or concurrent treatments:
•Treatment with antipsychotics, anxiolytics, soporifics or muscle relaxants started within the two months preceding the study.
•Treatment with intraoral implants during the study or in the two months preceding the study.
•Criteria related to lifestyle: Excessive alcohol consumption (WHO definition: more than two glasses per day for a woman and more than three for a man).

Outcomes

Primary Outcomes

Overall relief (from 0% to 100%) based on the ratio of "complaint after treatment" to "complaint before treatment". Multiple measurements related to both pain and functional incapacity are aggregated to arrive at one reported value: complaint

Time Frame: Beginning (day 0); during treatment (day 30 and day 90); end (day 180)

Patient's complaint is calculated: * By integrating the weighting of both pain (P) and functional incapacity (FI) parameters in the complaint. 11 possibilities: \[100% P - 0% FI\] OR \[90% P - 10% FI\] OR \[80% P - 20% FI\] etc. * Patient's complaint = Pain and/or functional incapacity * Assessement of pain integrates 2 or 3 or 4 parameters: 2 are constant (intensity and frequency), 2 are optional (quality of life and drugs) because some painful patient don't take drug or don't have an altered quality of life. If there are 2 parameters, each = 50%; if 3 parameters, each = 33,3%; if 4 parameters, each = 25% * The scoring of the 4 pain parameters is based on questionnaires: Intensity: GCPS v2.0 (part 1): Score 0 to 100; Frequency (last month): Score 0 to 30; Drug: number of gram of the most specific medication (last month); Quality of life: GCPS v2.0 (part 2): score 0 to 6 * Assessement of functional incapacity integrates 1 parameter: the JFLS-20 questionnaire (score from 0 to 200)

Secondary Outcomes

Evidence of a change from baseline in the "intensity" component of cervico-maxillo-facial pain (a component of the primary outcome measure), on the basis of a questionnaire called "the Graded Chronic Pain Scale Version 2 (GCPS v2.0) (part 1)".(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in the "impact on quality of life" component of facial pain (a component of the primary outcome measure), on the basis of questionnaire called "the Graded Chronic Pain Scale Version 2 (GCPS v2.0) (part 2)".(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in the "frequency" component of facial pain (a component of the primary outcome measure), on the basis of a questionnaire developed by the authors.(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in the "taking the most specific medication for painful attacks" component of facial pain (a component of the primary outcome measure), on the basis of a questionnaire developed by the authors.(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in functional incapacity (a component of the primary outcome measure), on the basis of a questionnaire called " the Jaw Functional Limitation Scale (JFLS-20)".(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in oral behaviors induced by hypertonia, on the basis of a questionnaire developed by the authors and called "the short version of the Oral Behavior Checklist (OBC)".(Beginning (day 0); during treatment (day 30 and day 90); end (day 180))
Evidence of a change from baseline in dysacusis and feelings of dizziness, on the basis of a specific questionnaire developed by the authors.(Beginning (day 0) and end (day 180))
Evidence of a change from baseline in the patient's compliance with the treatment, on the basis of a questionnaire developed by the authors.(During treatment (day 30 and day 90) and end (day 180))
Evidence of the patient's subjective impressions of the treatment, on the basis of a questionnaire developed by the authors.(end (day 180))
Evidence of correlations between the patient's psychological state (assessed with the HAD and SCL-90R) and the therapeutic efficacy of the approach (assessed by the patient's overall relief).(Beginning (day 0))
Evidence of correlations between the patient's psychological state (assessed with the HAD and SCL-90R) and compliance with the treatment (assessed with a numerical scale created by the team in anticipation of the study).(Beginning (day 0))
Evidence of the percentage of subjects diagnosed as hypertonic among all the patients diagnosed as having TMD (whether or not included in the study) by tracking the patients with a flowchart developed by the authors.(end (day 180))